Melinda Telli, M.D. (@melindatelli) header
Melinda Telli, M.D. (@melindatelli) profile picture

Director of the Breast Cancer Program @StanfordCancer

Stanford University
Joined December 2012
Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)Photo by Melinda Telli, M.D. (@melindatelli)
Love this … “In a crowded therapy landscape, efficacy is only the first anchor” - Ines Vaz-Luis #ESMOBreast
1
1
12
389
Although giredestrant + everolimus showed improved PFS in both mutESR1 and ITT (wt and mutESR1), an exploratory analysis suggests that the mutESR1 population is driving the benefit in the ITT group, with no difference in PFS for the wt subgroup analysis. #ESMO25 @OncoAlert
1
17
1
46
5,702
.@CarmenCriscit brilliantly reviews & contextualizes 2 ph1 studies w/ICI 🔹 ivonescimab in combo w/chemo as 1L tx for TNBC - bispecific Ab 🎯 PD-1 & VEGF 🔹 PM8002/BNT327 in combo w nab-paclitaxel for 1L tx mTNBC - bispecific Ab 🎯 PD-L1 & VEGF-A #ESMO24 @OncoAlert
18
39
3,018
Melinda Telli, M.D. retweeted
Great discussion on the rationale of combining ICI and antiangiogenics by @CarmenCriscit today at #ESMO2024 👏👏 Check it out if you missed it! @OncoAlert #bcsm @myESMO
1
14
1
25
2,046
Listen now! 🎧 In this new CME-certified podcast Sara Tolaney, MD (@stolaney1) and Melinda Telli, MD (@melindatelli) discuss novel #ADCs in Advanced #BreastCancer. Listen here ⬇️⬇️ clinicaloptions.com/CE-CME/o…
9
23
1,728
My sincere thanks @SABCSSanAntonio! We have come a long way in TNBC and it felt great to share a summary of all of those advances today. We will keep striving 🙌🏻 #SABCS23
Melinda L. Telli discussed "Recent Advances in Triple Negative Breast Cancer" during her plenary lecture this morning at #SABCS23. @MelindaTelli @UTHealthSAMDA @AACR @OncoAlert
1
4
57
6,380
Melinda Telli, M.D. retweeted
Pre-ASCO treat: #CAPItello291 is now out on NEJM! Meaningful improvement in PFS with capivasertib added to fulvestrant, particularly in Akt-path altered tumors (40%); benefit less clear in non-altered tumors. Tox: diarrhea (72%), rash (38%) & nausea (34%). nejm.org/doi/full/10.1056/NE…
2
56
2
163
30,575
Dr. Julia Ransohoff of @StanfordMed @StanfordHealth is recognized as this year’s Paul Carbone, MD Fellowship Award recipient by @eaonc co-chair Dr. Mitchell Schnall #CancerResearch #ClinicalTrials #BreastCancer #bcsm
4
1
10
2,554
Big news: NATALEE Trial positive at interim analysis. More details to come…
9
25
3,666
Melinda Telli, M.D. retweeted
#SABCS22 sara Hurvitz presents DB03 now showing sign OS benefit although medians not reached in either arm. Still no deaths from ILD, overall rate 15.2%. Incredible PFS maintained. Little cumulative tox. Truly an amazing advance for pts. @OncoAlert
1
22
2
85
Melinda Telli, M.D. retweeted
🔥HOT OFF THE PRESS🔥 – “A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes” by @joshuagruber @melindatelli & Co. Read it here👇 go.nature.com/3Tuz6iZ rdcu.be/cXNOl
8
17
Thank you @SusanGKomen for your support of this work 🙏🏻
A new study by Komen researchers @joshuagruber @anosheha & Komen Scholar @melindatelli identifies patients with advanced #HER2- #breastcancer and inherited PALB2 mutations are uniquely sensitive to PARP inhibitor drugs. Read the full report here: go.nature.com/3yQLkdI
4
Melinda Telli, M.D. retweeted
Review of pathologic complete response (pCR) shows that evidence currently available does not support pCR used alone as a reliable surrogate endpoint in neoadjuvant randomized controlled trials for breast cancer. ja.ma/3SJNnIu #BCSM
➡️Were you ever told to read "Simone's Maxims?" as the model for how to navigate academic medicine? 👇🏼Check this out! We've re-imagined the maxims to serve a diverse workforce. Please share! ascopubs.org/doi/abs/10.1200… @YaleCancer @YaleHemOnc @YaleMedDEI @YaleMed
1
11
1
31
Melinda Telli, M.D. retweeted
Do you work with trainees or collaborators who may be in the dark about the importance of statistical power? A new and fun analogy illuminates what they need to know! @BaiocchiMike doi.org/10.1093/aje/kwac019
2
26
9
30
Melinda Telli, M.D. retweeted
#ASCO22 open access educational read #bcsm ‘Integrating Immunotherapy Into the Treatment Landscape for Patients With #tnbc Triple-Negative Breast Cancer’ ascopubs.org/doi/full/10.120… with @LoiblSibylle @melindatelli @OncoAlert
1
24
1
57
Melinda Telli, M.D. retweeted
👉Controversy finally settled.. Ablating all sites of disease in oligometastatic breast cancer #bcsm does NOT improve outcome per randomized NRG-BR002. PFS in pts undergoing ablation of mets + SOC (mostly w SBRT) is 19.5 months vs 23 months in pts who received SOC alone. #ASCO22
1
5
10
Back home from @ASCO! Excited and grateful to @ConquerCancerFd to have received the Women Who Conquer Cancer YIA in Recognition of an Outstanding Latina Researcher alongside the amazing @AnaVManana. Thank you, @manalipatelmd for your mentorship and guidance.
4
12
6
124
So, Enhertu has dramatic effects in HER2 3+, and now very impressive findings in HER2 1+ or 2+ (HR same for each group). The question is: is HER2 testing relevant AT ALL for Enhertu activity? The guess is: it won't matter. Looks like an agent with near universal activity.
6
29
173
Melinda Telli, M.D. retweeted
CNS activity of T-DXd. In 17 pts w/HER2+ BCBM, CNS ORR 73% (11/15) in pts with measurable CNS mets including 7/10 pts with active BCBM. Median # of T-DXd cycles was 12 (2-24) with 42% (7/17) remaining on tx at data cutoff. @SKabrajiMD @drsarahsam @CareyAnders1 @rashmikmurthy
1
20
3
59